Gou S M, Wu H S
Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhonghua Yi Xue Za Zhi. 2021 Mar 16;101(10):716-721. doi: 10.3760/cma.j.cn112137-20201121-03157.
Pancreatic cancer has a high degree of malignancy, with a poor prognosis. Although surgical resection remains the only way to cure pancreatic cancer at present, the treatment mode has changed from "surgery priority" to "multidisciplinary cooperation" with the development of adjuvant therapy. Neoadjuvant therapy has been documented to increase the R0 resection rate of borderline resectable and locally advanced pancreatic cancer and improve the prognosis of the patients, and there has been a consensus on neoadjuvant therapy for these patients. However, there is still much controversy in the choice of neoadjuvant chemotherapy, the status of radiotherapy, imaging and pathological evaluation after neoadjuvant therapy for pancreatic cancer.
胰腺癌具有高度恶性，预后较差。尽管手术切除目前仍是治愈胰腺癌的唯一方法，但随着辅助治疗的发展，治疗模式已从“手术优先”转变为“多学科协作”。新辅助治疗已被证明可提高可切除边界和局部晚期胰腺癌的R0切除率，并改善患者预后，对于这些患者的新辅助治疗已达成共识。然而，在胰腺癌新辅助化疗的选择、放疗的地位、新辅助治疗后的影像学及病理评估等方面仍存在诸多争议。
